Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Laigo Bio has raised $6.4M in total funding. The most recent round was Seed. The last funding was announced in March 2026.
Laigo Bio's investors include Kurma Partners, Eurazeo, ARGOBIO, ROM Utrecht Region, Biovance Capital.
Laigo Bio is headquartered in Utrecht, The Netherlands.
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.
Laigo Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Laigo Bio — Funding & Investors." VCBacked, March 23, 2026, https://www.vcbacked.co/company/laigo-bio. Accessed August 13, 2026.
VCBacked. (2026). Laigo Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/laigo-bio
{{cite web |title=Laigo Bio — Funding & Investors |url=https://www.vcbacked.co/company/laigo-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated